|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
585,690,000 |
Market
Cap: |
178.65(B) |
Last
Volume: |
1,924,998 |
Avg
Vol: |
2,723,980 |
52
Week Range: |
$217.36 - $324.56 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ-100 |
|
S&P 100 |
|
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 499 |
Guru Rank Value : 3 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
2,117 |
2,117 |
23,771 |
31,503 |
Total Sell Value |
$662,802 |
$662,802 |
$6,471,520 |
$8,438,219 |
Total People Sold |
1 |
1 |
3 |
6 |
Total Sell Transactions |
1 |
1 |
4 |
8 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bradway Robert A |
Chairman, CEO and President |
|
2021-05-03 |
4 |
D |
$239.64 |
$682,974 |
D/D |
(2,850) |
594,173 |
|
- |
|
Louie Linda H. |
VP, Finance & CAO |
|
2021-05-01 |
4 |
D |
$239.64 |
$4,314 |
D/D |
(18) |
8,283 |
|
- |
|
Grygiel Nancy A. |
SVP & CCO |
|
2021-05-01 |
4 |
D |
$239.64 |
$14,858 |
D/D |
(62) |
12,516 |
|
- |
|
Johnston Lori A |
EVP, HR |
|
2021-05-01 |
4 |
D |
$239.64 |
$85,072 |
D/D |
(355) |
37,700 |
|
- |
|
Graham Jonathan P |
EVP, Gen. Counsel & Secy. |
|
2021-05-01 |
4 |
D |
$239.64 |
$139,231 |
D/D |
(581) |
47,181 |
|
- |
|
Piacquad David |
SVP, Business Development |
|
2021-05-01 |
4 |
D |
$239.64 |
$33,310 |
D/D |
(139) |
45,007 |
|
- |
|
Reese David M |
EVP, Research and Development |
|
2021-05-01 |
4 |
D |
$239.64 |
$265,761 |
D/D |
(1,109) |
45,217 |
|
- |
|
Santos Esteban |
EVP, Operations |
|
2021-05-01 |
4 |
D |
$239.64 |
$156,006 |
D/D |
(651) |
51,793 |
|
- |
|
Bradway Robert A |
Chairman, CEO and President |
|
2021-05-01 |
4 |
D |
$239.64 |
$695,435 |
D/D |
(2,902) |
597,023 |
|
- |
|
Louie Linda H. |
VP, Finance & CAO |
|
2021-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
300 |
8,301 |
|
- |
|
Grygiel Nancy A. |
SVP & CCO |
|
2021-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
584 |
12,578 |
|
- |
|
Johnston Lori A |
EVP, HR |
|
2021-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,296 |
38,055 |
|
- |
|
Griffith Peter H. |
EVP & CFO |
|
2021-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,338 |
25,960 |
|
- |
|
Gordon Murdo |
EVP Global Commercial Ops |
|
2021-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
4,172 |
45,630 |
|
- |
|
Graham Jonathan P |
EVP, Gen. Counsel & Secy. |
|
2021-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,797 |
47,762 |
|
- |
|
Piacquad David |
SVP, Business Development |
|
2021-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
709 |
45,146 |
|
- |
|
Reese David M |
EVP, Research and Development |
|
2021-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
4,006 |
46,326 |
|
- |
|
Santos Esteban |
EVP, Operations |
|
2021-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,964 |
52,444 |
|
- |
|
Holley Charles M |
Director |
|
2021-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
167 |
4,256 |
|
- |
|
Bradway Robert A |
Chairman, CEO and President |
|
2021-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
13,280 |
599,925 |
|
- |
|
Kullman Ellen Jamison |
Director |
|
2021-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
136 |
7,094 |
|
- |
|
Reese David M |
EVP, Research and Development |
|
2021-04-27 |
4 |
D |
$255.52 |
$44,460 |
D/D |
(174) |
42,320 |
|
- |
|
Grygiel Nancy A. |
SVP & CCO |
|
2021-04-27 |
4 |
D |
$255.52 |
$14,565 |
D/D |
(57) |
11,994 |
|
- |
|
Bradway Robert A |
Chairman, CEO and President |
|
2021-04-27 |
4 |
D |
$255.52 |
$668,696 |
D/D |
(2,617) |
586,645 |
|
- |
|
Graham Jonathan P |
EVP, Gen. Counsel & Secy. |
|
2021-04-27 |
4 |
D |
$255.52 |
$144,113 |
D/D |
(564) |
43,965 |
|
- |
|
2206 Records found
|
|
Page 13 of 89 |
|
|